- Home
- GOCO vs SLGL Comparison
GOCO vs SLGL Comparison
Compare GOCO & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- SLGL
- Stock Information
- Founded
- GOCO 2001
- SLGL 1997
- Country
- GOCO United States
- SLGL Israel
- Employees
- GOCO N/A
- SLGL N/A
- Industry
- GOCO Specialty Insurers
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- GOCO Finance
- SLGL Health Care
- Exchange
- GOCO Nasdaq
- SLGL Nasdaq
- Market Cap
- GOCO 64.9M
- SLGL 69.1M
- IPO Year
- GOCO 2020
- SLGL 2018
- Fundamental
- Price
- GOCO $4.80
- SLGL $24.35
- Analyst Decision
- GOCO Hold
- SLGL
- Analyst Count
- GOCO 1
- SLGL 0
- Target Price
- GOCO $12.00
- SLGL N/A
- AVG Volume (30 Days)
- GOCO 45.0K
- SLGL 32.4K
- Earning Date
- GOCO 11-06-2025
- SLGL 11-14-2025
- Dividend Yield
- GOCO N/A
- SLGL N/A
- EPS Growth
- GOCO N/A
- SLGL N/A
- EPS
- GOCO N/A
- SLGL N/A
- Revenue
- GOCO $822,444,000.00
- SLGL $23,931,000.00
- Revenue This Year
- GOCO $2.06
- SLGL N/A
- Revenue Next Year
- GOCO $5.47
- SLGL $31.17
- P/E Ratio
- GOCO N/A
- SLGL N/A
- Revenue Growth
- GOCO 17.46
- SLGL 264.86
- 52 Week Low
- GOCO $4.65
- SLGL $4.01
- 52 Week High
- GOCO $21.00
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- GOCO 38.80
- SLGL 59.60
- Support Level
- GOCO $4.76
- SLGL $23.13
- Resistance Level
- GOCO $5.01
- SLGL $24.85
- Average True Range (ATR)
- GOCO 0.24
- SLGL 2.20
- MACD
- GOCO 0.01
- SLGL -0.53
- Stochastic Oscillator
- GOCO 18.74
- SLGL 37.22
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.